Premium
Kaposi's sarcoma after T‐cell costimulation blockade with abatacept in rheumatoid arthritis: a case report
Author(s) -
Olivo D.,
Grembiale R. D.,
Tallarigo F.,
Russo E.,
De Sarro G.,
Ursini F.
Publication year - 2017
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12510
Subject(s) - abatacept , rheumatoid arthritis , medicine , blockade , arthritis , sarcoma , dermatology , immunology , pathology , receptor , lymphoma , rituximab
Summary What is known and objective Kaposi's sarcoma ( KS ) is a malignant neoplasm caused by HHV ‐8, a pathogen that leads to endothelial cell transformation when host defences are weakened. Case description Here we report the first case of KS during treatment with abatacept, a biologic agent targeting T‐cell costimulation. The patient was a 64‐year‐old female with rheumatoid arthritis who developed multiple firm, purple‐reddish nodules on the dorsal aspect of the right hand. Histological examination confirmed KS . What is new and conclusion Although a direct causal relationship between KS development and abatacept treatment cannot be proved, we hypothesize a role for costimulation blockade.